Lack of TEL/AML1 fusion in pediatric AML: further evidence for lineage specificity of TEL/AML1

Leuk Res. 1998 May;22(5):461-4. doi: 10.1016/s0145-2126(98)00023-x.

Abstract

Background: The TEL/AML1 fusion associated with t(12;21)(p13;q22) is the most common gene rearrangement in childhood malignancy, occurring in approximately 25% of pediatric acute lymphoblastic leukemia. The TEL/AML1 rearrangement is cryptic at the cytogenetic level but confers a favorable prognosis. The AML1 gene was first identified by virtue of its involvement in adult and pediatric acute myeloid malignancies associated with t(8;21) and t(3;21)(q26;q22.1). We have therefore determined the frequency of the TEL/AML1 fusion in pediatric myeloid leukemias by RT-PCR analysis.

Methods: Total RNA was isolated from cryopreserved bone marrow samples of 38 pediatric patients with AML. RNA quality was controlled for by amplification of the TEL gene. An RT-PCR assay was then used to test for the presence of the TEL/AML1 fusion.

Results: 29 patients had adequate RNA for analysis. Zero out of 29 pediatric AML patients had evidence for the TEL/AML1 fusion by RT-PCR.

Conclusions: The TEL/AML1 fusion does not occur in children with AML and suggests that the TEL/AML1 rearrangement is restricted in pediatric hematologic malignancy to B lineage ALL.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acute Disease
  • Adolescent
  • Cell Lineage / genetics
  • Child
  • Child, Preschool
  • Chromosomes, Human, Pair 12
  • Chromosomes, Human, Pair 21
  • Core Binding Factor Alpha 2 Subunit
  • Female
  • Humans
  • Leukemia, Myeloid / classification
  • Leukemia, Myeloid / genetics*
  • Male
  • Neoplasm Proteins / genetics*
  • Oncogene Proteins, Fusion*
  • Polymerase Chain Reaction
  • RNA / analysis
  • Translocation, Genetic / genetics*

Substances

  • Core Binding Factor Alpha 2 Subunit
  • Neoplasm Proteins
  • Oncogene Proteins, Fusion
  • TEL-AML1 fusion protein
  • RNA